EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
Investor briefing 30 March 2021.
EKF Diagnostics confirms that continued strong trading will result in the performance for the year ending 31 December 2020 being comfortably ahead of already upgraded market expectations.
EKF Diagnostics declares the distribution of shares in Trellus Health Limited.
A General Meeting was held to seek shareholder approval to distribute the company's holding in Trellus Health Limited.
Kantaro Biosciences, LLC has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test kit.
A Circular will today be sent to shareholders providing background to, details of and reasons for, a dividend in specie, to facilitate the spin-out of the Company’s shareholding in Trellus Health Limited to EKF’s shareholders.
Full year performance to further exceed market consensus
EKF to distribute Kantaro COVID-SeroKlir and COVID-SeroIndex quantitative COVID antibody tests in UK and Europe.